The antiphospholipid syndrome (APS), originally defined as the combination of venous or
arterial thrombotic events, recurrent fetal loss, and, frequently, a moderate thrombocytopenia …

Background Systemic lupus erythematosus is a heterogeneous autoimmune disease that is
associated with B-cell hyperactivity, autoantibodies, and increased concentrations of B-…

Background: There is concern that exogenous female hormones may worsen disease activity
in women with systemic lupus erythematosus (SLE). Objective: To evaluate the effect of …

Genome-wide association studies have recently identified at least 15 susceptibility loci for
systemic lupus erythematosus (SLE). To confirm additional risk loci, we selected SNPs from …

Objective In systemic lupus erythematosus (SLE), disease activity and glucocorticoid (GC)
exposure are known to contribute to irreversible organ damage. We aimed to examine the …

The TNFAIP3 (tumor necrosis factor alpha–induced protein 3) gene encodes a ubiquitin
editing enzyme, A20, that restricts NF-κB–dependent signaling and prevents inflammation. We …

Cardiovascular disease (CVD) and autoimmune diseases (ADs) are the first and third highest
causes of death in the USA, respectively. Men have an increased incidence of the majority …

Objective To assess the safety, tolerability, biologic activity, and efficacy of belimumab in
combination with standard of care therapy (SOC) in patients with active systemic lupus …

Lupus nephritis is a potentially fatal autoimmune disease for which the current treatment is
ineffective and often toxic. To develop mechanistic hypotheses of disease, we analyzed …

Objective To describe a new systemic lupus erythematosus (SLE) responder index (SRI) based
on a belimumab phase II SLE trial and demonstrate its potential utility in SLE clinical trials…